OBJECTIVE: Our previous study in heterozygous Ren-2 transgenic rats (TGR) demonstrated that long-term treatment with endothelin receptor A (ETA) blocker atrasentan added to the renin-angiotensin system (RAS) blockade had renoprotective effects in a model of chronic kidney disease (CKD) induced by partial nephrectomy. Since ETA blockade is known to cause edema, we were interested whether diuretic treatment added to this therapy would be beneficial. DESIGN AND METHODS: Partial nephrectomy (NX) was performed at the age of 3 months in TGR rats which were subjected to: (i) RAS blockade alone (angiotensin receptor blocker losartan and angiotensin converting enzyme inhibitor trandolapril), (ii) combined RAS (losartan and trandolapril) and ETA receptor blockade (atrasentan), or (iii) diuretic (hydrochlorothiazide) added to the combined RAS + ETA blockade for 50 weeks following NX. RESULTS: At the end of the study systolic blood pressure and cardiac hypertrophy were similarly decreased in all treated groups. Survival was significantly improved by ETA receptor blockade added to RAS blockade with no further effects of diuretic treatment. However, additional diuretic treatment combined with RAS + ETA blockade decreased body weight and had beneficial renoprotective effects - reductions of both kidney weight and kidney damage markers. Proteinuria gradually increased in rats treated with RAS blockade alone, while it was substantially lowered by additional ETA blockade. In rats treated with additional diuretic, proteinuria was progressively reduced throughout the experiment. CONCLUSION: A diuretic added to the combined RAS and ETA blockade has late renoprotective effects in CKD induced by partial nephrectomy in Ren-2 transgenic rats. The diuretic improved: renal function (evaluated as proteinuria and creatinine clearance), renal morphology (kidney mass, glomerular volume), and histological markers of kidney damage (glomerulosclerosis index, tubulointerstitial injury).

Department of Experimental Hypertension Institute of Physiology Czech Academy of Sciences Prague Czechia

Department of Pathology 3rd Faculty of Medicine Charles University Prague Czechia

Department of Renal and Body Fluid Physiology Mossakowski Medical Research Centre Polish Academy of Sciences Warsaw Poland

Institute for Clinical and Experimental Medicine Prague Czechia

Zobrazit více v PubMed

Arias S. C., Souza R. A., Malheiros D. M., Fanelli C., Fujihara C. K., Zatz R. (2016). An association of losartan-hydrochlorothiazide, but not losartan-furosemide, completely arrests progressive injury in the remnant kidney. Am. J. Physiol. Renal Physiol. 310 F135–F143. 10.1152/ajprenal.00388.2015 PubMed DOI

Arias S. C., Valente C. P., Machado F. G., Fanelli C., Origass C. S., de Brito T., et al. (2013). Regression of albuminuria and hypertension and arrest of severe renal injury by a losartan-hydrochlorthiazide association in a model of very advanced nephropathy. PLoS One 8:e56215. 10.1371/journal.pone.0056215 PubMed DOI PMC

Brenner B. M., Lawler E. V., Mackenzie H. S. (1996). The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int. 49 1774–1777. 10.1038/ki.1996.265 PubMed DOI

Breyer M. D., Susztak K. (2016). Developing treatments for chronic kidney disease in the 21st century. Semin. Nephrol. 36 436–447. 10.1016/j.semnephrol.2016.08.001 PubMed DOI PMC

Čertíková Chábová V., Červenka L. (2017). The dilemma of dual renin-angiotensin system blockade in chronic kidney disease: why beneficial in animal experiments but not in the clinic? Physiol. Res. 66 181–192. PubMed

Čertíková Chábová V., Vernerová Z., Kujal P., Husková Z., Škaroupková P., Tesař V., et al. (2014). Addition of ETA receptor blockade increases renoprotection provided by renin-angiotensin system blockade in 5/6 nephrectomized Ren-2 transgenic rats. Life Sci. 118 297–305. 10.1016/j.lfs.2013.12.018 PubMed DOI

Cirillo M., Marcarelli F., Mele A. A., Romano M., Lombardi C., Bilancio G. (2014). Parallel-group 8-week study on chlorthalidone effects in hypertensives with low kidney function. Hypertension 63 692–697. 10.1161/HYPERTENSIONAHA.113.02793 PubMed DOI

Cohen J. (2013). Statistical Power Analysis for the Behavioral Sciences. Cambridge, MA: Academic press.

Culshaw G. J., MacIntyre I. M., Dhaun N., Webb D. J. (2015). Endothelin in nondiabetic chronic kidney disease: preclinical and clinical studies. Semin. Nephrol. 35 176–187. 10.1016/j.semnephrol.2015.03.002 PubMed DOI

Czopek A., Moorhouse R., Webb D. J., Dhaun N. (2016). Therapeutic potential of endothelin receptor antagonism in kidney disease. Am. J. Physiol. Renal Physiol. Regul. Integr. Comp. Physiol. 310 R388–R397. 10.1152/ajpregu.00478.2015 PubMed DOI

Davenport A. P., Hyndman K. A., Dhaun N., Southan C., Kohan D. E., Pollock J. S., et al. (2016). Endothelin. Pharmacol. Rev. 68 357–418. 10.1124/pr.115.011833 PubMed DOI PMC

Davenport A. P., Kuc R. E., Southan C., Maguire J. J. (2018). New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine. Physiol. Res. 67(Suppl. 1), S37–S54. PubMed

de Zeeuw D., Coll B., Andress D., Brennan J. J., Tang H., Houser M., et al. (2014). The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J. Am. Soc. Nephrol. 25 1083–1093. 10.1681/ASN.2013080830 PubMed DOI PMC

Dhaun N., Webb D. J. (2019). Endothelins in cardiovascular biology, and therapeutics. Nat. Rev. Cardiol. 16 491–502. 10.1038/s41569-019-0176-173 PubMed DOI

Fujihara C. K., Velho M., Malheiros D. M., Zatz R. (2005). An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int. 67 1913–1924. 10.1111/j.1523-1755.2005.00290.x PubMed DOI

Fuwa D., Fukuda M., Ogiyama Y., Sato R., Mizuno M., Miura T., et al. (2016). Addition of hydrochlorothiazide to angiotensin receptor blocker therapy can achieve a lower sodium balance with no acceleration of intrarenal renin angiotensin system in patients with chronic kidney disease. J. Renin Angiotens. Aldoster. Syst. 17:1470320316652032. 10.1177/1470320316652032 PubMed DOI PMC

Heerspink H. J. L., Parving H. H., Andress D. L., Bakris G., Correa-Rotter R., Hou F. F., et al. (2019). SONAR committees and investigators. atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 393 1937–1947. 10.1016/S0140-6736(19)30772-X PubMed DOI

Jin C., Jeon Y., Kleven D. T., Pollock J. S., White J. J., Pollock D. M. (2014). Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome. J. Pharmacol. Exp. Ther. 351 467–473. 10.1124/jpet.114.215566 PubMed DOI PMC

Kohan D. E., Barton M. (2014). Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int. 86 896–904. 10.1038/ki.2014.143 PubMed DOI PMC

Kohan D. E., Pollock D. M. (2013). Endothelin antagonists for diabetic and non-diabetic chronic kidney disease. Br. J. Clin. Pharmacol. 76 573–579. 10.1111/bcp.12064 PubMed DOI PMC

Komers R., Gipson D. S., Nelson P., Adler S., Srivastava T., Derebail V. K., et al. (2017). Efficacy and safety of sparsentan compared with irbesartan in patients with primary focal segmental glomerulosclerosis: randomized, controlled trial design (DUET). Kidney Int. Rep. 2 654–664. 10.1016/j.ekir.2017.02.019 PubMed DOI PMC

Komers R., Plotkin H. (2016). Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 310 R877–R884. 10.1152/ajpregu.00425.2015 PubMed DOI PMC

Kriz W., Lemley K. V. (2015). A potential role for mechanical forces in the detachment of podocytes and the progression of CKD. J. Am. Soc. Nephrol. 26 258–269. 10.1681/ASN.2014030278 PubMed DOI PMC

Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. (1951). Protein measurement with the folin phenol reagent. J. Biol. Chem. 193 265–275. PubMed

Mann J. F., Green D., Jamerson K., Ruilope L. M., Kuranoff S. J., Littke T., et al. (2010). ASCEND study group. avosentan for overt diabetic nephropathy. J. Am. Soc. Nephrol. 21 527–535. 10.1681/ASN.2009060593 PubMed DOI PMC

Maquigussa E., Paterno J. C., de Oliveira Pokorny G. H., da Silva Perez M., Varela V. A., da Silva Novaes A., et al. (2018). Klotho and PPAR Gamma activation mediate the renoprotective effect of losartan in the 5/6 nephrectomy model. Front. Physiol. 9:1033. 10.3389/fphys.2018.01033 PubMed DOI PMC

Morales E., Caro J., Gutierrez E., Sevillano A., Aunon P., Fernandez C., et al. (2015). Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease. Kidney Int. 88 1434–1441. 10.1038/ki.2015.249 PubMed DOI

Morrison A. B. (1962). Experimentally induced chronic renal insufficiency in the rat. Lab. Invest. 11 321–333. PubMed

Mullins J. J., Peters J., Ganten D. (1990). Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 344 541–544. 10.1038/344541a0 PubMed DOI

Nakano Y., Hirano T., Uehara K., Nishibayashi S., Hattori K., Aihara M., et al. (2008). New rat model induced by anti-glomerular basement membrane antibody shows severe glomerular adhesion in early stage and quickly progress to end-stage renal failure. Pathol. Int. 58 361–370. 10.1111/j.1440-1827.2008.02237.x PubMed DOI

Raij L. (2005). The pathophysiological basis for blocking the renin-angiotensin system in hypertensive patients with renal disease. Am. J. Hypertens. 18 95S–99S. 10.1016/j.amjhyper.2004.11.040 PubMed DOI

Rakusan D., Kujal P., Kramer H. J., Husková Z., Vanourková Z., Vernerová Z., et al. (2010). Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. Am. J. Physiol. Renal Physiol. 299 F758–F766. 10.1152/ajprenal.00259.2010 PubMed DOI

Saito T., Sumithran E., Glasgow E. F., Atkins R. C. (1987). The enhancement of aminonucleoside nephrosis by the co-administration of protamine. Kidney Int. 32 691–699. 10.1038/ki.1987.262 PubMed DOI

Samad M. A., Kim U. K., Kang J. J., Ke Q., Kang P. M. (2015). Endothelin a receptor antagonist, atrasentan, attenuates renal and cardiac dysfunction in dahl salt-hypertensive rats in a blood pressure independent manner. PLoS One 10:e0121664. 10.1371/journal.pone.0121664 PubMed DOI PMC

Sedláková L., Čertíková Chábová V., Doleželová Š, Škaroupková P., Kopkan L., Husková Z., et al. (2017). Renin-angiotensin system blockade alone or combined with ETA receptor blockade: effects on the course of chronic kidney disease in 5/6 nephrectomized Ren-2 transgenic rats. Clin. Exp. Hypertens. 39 183–195. 10.1080/10641963.2016.1235184 PubMed DOI

Sinha A. D., Agarwal R. (2015). Thiazide diuretics in chronic kidney disease. Curr. Hypertens. Rep. 17:13. 10.1007/s11906-014-0525-x PubMed DOI

Thomopoulos C., Parati G., Zanchetti A. (2015). Effects of blood pressure lowering on outcome incidence in hypertension: 4. effects of various classes of antihypertensive drugs–overview and meta-analyses. J. Hypertens. 33 195–211. 10.1097/HJH.0000000000000447 PubMed DOI

Trachtman H., Nelson P., Adler S., Campbell K. N., Chaudhuri A., Derebail V. K., et al. (2018). DUET study group. DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J. Am. Soc. Nephrol. 29 2745–2754. 10.1681/ASN.2018010091 PubMed DOI PMC

Vaněčková I., Hojná S., Kadlecová M., Vernerová Z., Kopkan L., Červenka L., et al. (2018). Renoprotective effects of ETA receptor antagonists therapy in experimental non-diabetic chronic kidney disease: is there still hope for the future? Physiol. Res. 67(Suppl. 1), S55–S67. PubMed

Vaněčková I., Kujal P., Husková Z., Vaňourková Z., Vernerová Z., Čertíková Chábová V., et al. (2012). Effects of combined endothelin a receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats. Kidney Blood Press. Res. 35 382–392. 10.1159/000336823 PubMed DOI

Vaněčková I., Řezáčová L., Kuneš J., Zicha J. (2016). Moderate additive effects of endothelin receptor a blockade in Ren-2 transgenic rats subjected to various types of RAS blockade. Life Sci. 159 127–134. 10.1016/j.lfs.2016.01.020 PubMed DOI

Vercauteren M., Trensz F., Pasquali A., Cattaneo C., Strasser D. S., Hess P., et al. (2017). Endothelin ETA receptor blockade, by activating ETB receptors, increases vascular permeability and induces exaggerated fluid retention. J. Pharmacol. Exp. Ther. 361 322–333. 10.1124/jpet.116.234930 PubMed DOI

Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., et al. (1988). A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 411–415. 10.1038/332411a0 PubMed DOI

Zhong J., Yang H. C., Fogo A. B. (2017). A perspective on chronic kidney disease progression. Am. J. Physiol. Renal. Physiol. 312 F375–F384. 10.1152/ajprenal.00266.2016 PubMed DOI PMC

Zoja C., Abbate M., Remuzzi G. (2006). Progression of chronic kidney disease: insight from animal models. Curr. Opin. Nephrol. Hypertens. 15 250–257. 10.1097/01.mnh.0000222691.53970.83 PubMed DOI

Endothelin type A receptor blockade attenuates aorto-caval fistula-induced heart failure in rats with angiotensin II-dependent hypertension